BPOM Targets Permit For Emergency Use Of Unair's Red And White Vaccine To Be Issued In June 2022

Head of the Food and Drug Supervisory Agency (BPOM) Penny K Lukito while leading a press conference related to booster vaccines at the BPOM RI Building, Central Jakarta, Monday (10/1/2022). ANTARA/Andi Firdaus

JAKARTA - The Head of the Food and Drug Supervisory Agency (BPOM) Penny K Lukito is targeting an Emergency Use Authorization (EUA) for the Universitas Airlangga (Unair) COVID-19 vaccine to be issued in June 2022.

"It is hoped that in early February there will be clinical trials for the Red and White vaccine from Airlangga University. If there are no significant obstacles, the target is June to get EUA," said Penny K Lukito at a press conference related to booster vaccines at the BPOM RI Building, Central Jakarta, as reported by Antara, Monday, January 10.

Penny said there were six candidates for the domestically produced Red and White Vaccine. The first was tested by the Eijkman Institute for Molecular Biology, the second was tested by the Indonesian Institute of Sciences (LIPI), the third by the Bandung Institute of Technology (ITB), the fourth by Airlangga University (Unair), the fifth was tested by the University of Indonesia (UI), and the sixth by the University of Gadjah Mada (UGM).

Penny said that the Red and White Vaccine Unair was a local academic with PT Biotis Pharmaceutical. Meanwhile, the role of BPOM is to assist in the development of vaccine research.

"We have issued an assessment document for research, development and production facilities that must meet the quality aspects and good laboratory work," he said. preclinical trials on animals.

"In addition to providing EUA, BPOM is building the independence of domestic vaccines through collaboration with researchers from Indonesia and other countries to conduct research, develop domestic vaccine infrastructure so that we can realize domestic vaccines," he said.